CompanyNSRXNYSETel Aviv - Yafo, L3

Nasus Pharma

Nasus Pharma develops intranasal powder therapies.

SEC EDGAR ClinicalTrials.gov nasuspharma.com

424B5Sep 18Latest SEC filing

Sep 18Latest story

September 2026

Nasus Pharma files to sell up to $8.5 million in shares via ATM offering

Sep 18FinancingNasus Pharma

August 2026

Nasus Pharma CFO Eyal Rubin to resign, interim successor named

Aug 19PeopleNasus Pharma

July 2026

Nasus Pharma names Brendan P. O'Grady CEO, succeeding Dan Teleman

Jul 28PeopleNasus Pharma